Biotech Values

[DewDiligence]

ENTA’s COVID-19 work had two components: 1) screening the company’s proprietary library of DAA compounds to see if any compound in the library happened to show a benefit, based on in vitro testing, in treating the acute pandemic; and 2) designing novel COVID-19-specific DAA compounds from the ground up, based on the premise that COVID-19 will be a heath concern for several years to come and that measured outbreaks will occur from time to time. (Even if there is an approved COVID-19 vaccine, not everyone will get vaccinated.)

We may presume that 1) did not pan out, or we would have heard something by now.

2), on the other hand, is a process where it will likely take a year or two to know whether ENTA has discovered something of value. ENTA has allocated one virologist and one chemist to this program (possibly on a part-time basis), so investors should not expect a market-moving announcement in the near future.